stockrow
Saturday 7 November 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- Revenue
- −57.1%
- EPS
- +99.5%
- Free cash flow
- +167.7%
Quarter to June 2026, against a year earlier
4.10
0.30
−6.82%
Follow IBO
Alert me
Impact Biomedical Inc. (IBO) P/E ratio
Impact Biomedical Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 21.7× (November 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 21.7×
Ten-year median
0.0×
Current reading's percentile
88
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| EXOZ eXoZymes Inc. compare | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| IBO Impact Biomedical Inc. | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)